Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 04, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Repurchased: 1,200,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,286.64 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,232,832,375 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 1,200,000 shares. Consequently, the total number of shares in issue decreased, while the proportion of Treasury shares held by the company now represents 9.06% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (1,200,000 shares at 1,286.64 pence) against the company's cash position in the most recent financial statements.
- Confirm the updated share count of 5,232,832,375 for calculating ownership percentages under Disclosure and Transparency Rules.
- Note that the company holds 474,194,158 Treasury shares, which do not carry voting rights but impact the denominator for voting calculations.